TrialClinical cancer research : an official journal of the American Association for Cancer Research2026

Anti-LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial.

Dongchen Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.